Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.
Brief Summary: The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.


Options:
A: Arm Label: FXIII17.5IU/Kg; Type: EXPERIMENTAL; Interventions: Drug: catridecacog | Arm Label: FXIII35IU/Kg; Type: EXPERIMENTAL; Interventions: Drug: catridecacog | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: catridecacog; Assigned to Arm(s): FXIII17.5IU/Kg | Intervention Type: DRUG; Name: catridecacog; Assigned to Arm(s): FXIII35IU/Kg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: WAS patients receiving Promacta; Type: EXPERIMENTAL; Interventions: Drug: Promacta | Arm Label: WAS patients for blood drawing only; Type: EXPERIMENTAL; Interventions: Diagnostic Test: blood drawing in patients with WAS | Arm Label: healthy children for blood drawing only; Type: PLACEBO_COMPARATOR; Interventions: Diagnostic Test: blood drawing in healthy controls | Intervention Type: DRUG; Name: Promacta; Assigned to Arm(s): WAS patients receiving Promacta | Intervention Type: DIAGNOSTIC_TEST; Name: blood drawing in patients with WAS; Assigned to Arm(s): WAS patients for blood drawing only | Intervention Type: DIAGNOSTIC_TEST; Name: blood drawing in healthy controls; Assigned to Arm(s): healthy children for blood drawing only
C: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW
D: Arm Label: 750 mcg AMG 531; Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 | Arm Label: Placebo Part B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Part A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 500 mcg AMG 531; Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 | Arm Label: 750 mcg AMG531 Part B; Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 | Intervention Type: BIOLOGICAL; Name: AMG 531; Assigned to Arm(s): 500 mcg AMG 531, 750 mcg AMG 531, 750 mcg AMG531 Part B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Part A, Placebo Part B

Answer: B